tetano
Editor, Senior Moderator
Vaccine
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.07.128 | How to Cite or Link Using DOI
Permissions & Reprints
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: A randomized, placebo-controlled trial
John J. Treanora, Corresponding Author Contact Information, E-mail The Corresponding Author, Hana El Sahlyb, James Kingc, Irene Grahamd, Ruvim Iziksone, Robert Kohbergerf, Peter Patriarcag and Manon Coxe
a University of Rochester, Rochester, NY, United States
b Baylor College of Medicine, Houston, TX, United States
c University of Maryland, Baltimore, MD, United States
d St. Louis University, St. Louis, MO, United States
e Protein Sciences Corporation, Meriden, CT, United States
f Blair & Co, Greenwich, CT, United States
g Biologics Consulting Group, Inc., Bethesda, MD, United States
Received 20 May 2011;
revised 27 July 2011;
accepted 27 July 2011.
Available online 9 August 2011.
Abstract
Background
Development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production is a high priority. We conducted this study to determine the protective efficacy a recombinant, baculovirus-expressed seasonal trivalent influenza virus hemagglutinin (rHA0) vaccine (FluBlok?).
Methods
Healthy adult subjects at 24 centers across the US were randomly assigned to receive a single injection of saline placebo (2304 subjects), or trivalent FluBlok containing 45 mcg of each rHA0 component (2344 subjects). Serum samples for assessment of immune responses by hemagglutination-inhibition (HAI) were taken from a subset of subjects before and 28 days after immunization. Subjects were followed during the 2007?2008 influenza season and combined nasal and throat swabs for virus isolation were obtained from subjects reporting influenza-like illness.
Results
Rates of local and systemic side effects were low, and the rates of systemic side effects were similar in the vaccine and placebo groups. HAI antibody responses were seen in 78%, 81%, and 52% of FluBlok recipients to the H1, H3, and B components, respectively. FluBlok was 44.8% (95% CI, 24.4%, 60.0%) effective in preventing culture-confirmed influenza meeting the CDC influenza-like illness case definition despite significant antigenic mismatch between the vaccine antigens and circulating viruses.
Conclusions
Trivalent rHA0 vaccine was safe, immunogenic and effective in the prevention of culture confirmed influenza illness, including protection against drift variants.
Highlights
► Randomized, placebo-controlled, multicenter assessment of efficacy of baculovirus expressed hemagglutinin vaccine for prevention of laboratory-documented influenza illness in healthy adults. ► Vaccine was safe and generated serum hemagglutination-inhibiting antibody responses against all three components in the majority of recipients. ► Influenza infections during surveillance were antigenically mismatched to the components in the vaccine. ► Vaccine efficacy was 44.8% (95% CI, 24.4%, 60.0%) for prevention of preventing culture-confirmed influenza illness.
http://www.sciencedirect.com/science/article/pii/S0264410X11011789
Article in Press, Uncorrected Proof - Note to users
doi:10.1016/j.vaccine.2011.07.128 | How to Cite or Link Using DOI
Permissions & Reprints
Protective efficacy of a trivalent recombinant hemagglutinin protein vaccine (FluBlok?) against influenza in healthy adults: A randomized, placebo-controlled trial
John J. Treanora, Corresponding Author Contact Information, E-mail The Corresponding Author, Hana El Sahlyb, James Kingc, Irene Grahamd, Ruvim Iziksone, Robert Kohbergerf, Peter Patriarcag and Manon Coxe
a University of Rochester, Rochester, NY, United States
b Baylor College of Medicine, Houston, TX, United States
c University of Maryland, Baltimore, MD, United States
d St. Louis University, St. Louis, MO, United States
e Protein Sciences Corporation, Meriden, CT, United States
f Blair & Co, Greenwich, CT, United States
g Biologics Consulting Group, Inc., Bethesda, MD, United States
Received 20 May 2011;
revised 27 July 2011;
accepted 27 July 2011.
Available online 9 August 2011.
Abstract
Background
Development of influenza vaccines that do not use embryonated eggs as the substrate for vaccine production is a high priority. We conducted this study to determine the protective efficacy a recombinant, baculovirus-expressed seasonal trivalent influenza virus hemagglutinin (rHA0) vaccine (FluBlok?).
Methods
Healthy adult subjects at 24 centers across the US were randomly assigned to receive a single injection of saline placebo (2304 subjects), or trivalent FluBlok containing 45 mcg of each rHA0 component (2344 subjects). Serum samples for assessment of immune responses by hemagglutination-inhibition (HAI) were taken from a subset of subjects before and 28 days after immunization. Subjects were followed during the 2007?2008 influenza season and combined nasal and throat swabs for virus isolation were obtained from subjects reporting influenza-like illness.
Results
Rates of local and systemic side effects were low, and the rates of systemic side effects were similar in the vaccine and placebo groups. HAI antibody responses were seen in 78%, 81%, and 52% of FluBlok recipients to the H1, H3, and B components, respectively. FluBlok was 44.8% (95% CI, 24.4%, 60.0%) effective in preventing culture-confirmed influenza meeting the CDC influenza-like illness case definition despite significant antigenic mismatch between the vaccine antigens and circulating viruses.
Conclusions
Trivalent rHA0 vaccine was safe, immunogenic and effective in the prevention of culture confirmed influenza illness, including protection against drift variants.
Highlights
► Randomized, placebo-controlled, multicenter assessment of efficacy of baculovirus expressed hemagglutinin vaccine for prevention of laboratory-documented influenza illness in healthy adults. ► Vaccine was safe and generated serum hemagglutination-inhibiting antibody responses against all three components in the majority of recipients. ► Influenza infections during surveillance were antigenically mismatched to the components in the vaccine. ► Vaccine efficacy was 44.8% (95% CI, 24.4%, 60.0%) for prevention of preventing culture-confirmed influenza illness.
http://www.sciencedirect.com/science/article/pii/S0264410X11011789